Personal Injury Lawyer - TheLawfirm.com

Free case review

1-855-464-0808
facebook logo google+ logo twitter logo youtube logo

Free Case Review

blank-spacer

 

Bad Drugs Androgel Lawsuit Insufficient Labelling

Plaintiff Tells Jury of AbbVie’s Failure to Label AndroGel

July 6, 2017

The plaintiff in a federal case in Illinois informed jurors that he nearly died after using the topical testosterone replacement drug AndroGel that had been insufficiently labeled for hazards.

Further, lawyers for plaintiff Jesse Mitchell alleged, AndroGel’s maker, AbbVie, was fully aware that its product was dangerous, but the company downplayed the product’s risks so that it could turn a larger profit.

Mitchell alleged that AbbVie ignored multiple warnings from the U.S. Food and Drug Administration (FDA) that AndroGel should be labeled to indicate that it had not been approved for the treatment of anything other than a specific set of hypogonadism conditions. AbbVie, the plaintiff alleged, promoted AndroGel as a broad-spectrum treatment, thus increasing health risks to users.

Topical testosterone replacement therapy drugs such as AndroGel have been linked to the risk of heart attacks.

Mitchell’s case is the second in a Multi-District Litigation (MDL) testosterone replacement drug case to be heard in court. The first case, heard in June 2017, ended in a mistrial.

Mitchell had been prescribed AndroGel in 2007 when tests showed that his levels of testosterone were low. After using the cream for some five years, Mitchell had a heart attack at the age of 44. In the suit, he alleges that AndroGel is to blame, in part because the product should have been labeled to indicate that it was not appropriate for use by men of his age.

AbbVie’s marketing campaign for AndroGel, the suit alleges, made no reference to patients’ age, though that factor is significant in determining the product’s efficacy.

The trial is ongoing in a Chicago courtroom.

If you believe that your health problems are the result of improperly prescribed or inadequately labeled prescription drugs such as testosterone replacement therapy medications, contact your doctor right away.

Then, contact the expert attorneys at TheLawFirm.com.

Talk with aN Attorney now!   

AndroGel Lawsuit Updates

ABBVIE ORDERED TO PAY $150 MILLION FOR FALSE ANDROGEL ADS

July 24, 2017
A federal jury in Illinois has ruled that pharmaceutical manufacturer AbbVie must pay $150 million in punitive damages for advertisements that made false claims about its topical testosterone replacement therapy drug AndroGel.

ABBVIE CLAIMS FDA NEVER REQUESTED STUDY OF ANDROGEL HEART ATTACK RISK

July 20, 2017
In a Chicago courtroom, an executive with drugmaker AbbVie asserted that the company had supplied the U.S. Food and Drug Administration (FDA) with information concerning the links between an elevated heart attack risk and its topical testosterone replacement therapy drug AndroGel, but that the agency never requested a formal study.

PLAINTIFF TESTIFIES THAT ANDROGEL DOES MORE HARM THAN GOOD

July 18, 2017
Plaintiff Jesse Mitchell testified in a Chicago courtroom that AndroGel, the topical testosterone replacement therapy drug manufactured by AbbVie, produced few measurable benefits but greatly increased his risk of heart attack.

FORMER FDA CHIEF SAYS ANDROGEL ADS WERE MISLEADING

July, 17, 2017
Former U.S. Food and Drug Administration (FDA) commissioner David Kessler told a jury in Illinois that the ads released by drugmaker AbbVie for its topical testosterone replacement drug AndroGel were misleading. The ads, Kessler said, promoted the drug for uses beyond those for which the FDA had granted it approval.

DOCTOR TESTIFIES ABOUT ANDROGEL’S HEART ATTACK RISKS

July 14, 2017
Northwestern University cardiologist Dr. Hossein Ardehali testified in a Chicago federal courtroom that there is enough evidence to suggest a link between testosterone replacement therapy drugs and an increased heart attack risk.

ABBVIE FACES LITIGATION ABOUT TESTOSTERONE-REPLACEMENT DRUGS

June 7, 2017
An Illinois federal jury has begun hearing a case in which the plaintiff alleges that Androgel, a testosterone-replacement drug manufactured by pharmaceutical giant AbbVie, deliberately misled doctors and patients about the drug’s side effects.

TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including: tv station logos

Real lawyers, real results!

no recovery, no fee!

SHARE THIS